Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Margarida Simao Rafael"'
Autor:
Sarah Cohen-Gogo, Avram E Denburg, Anita Villani, Nirav Thacker, Grace Egan, Margarida Simao Rafael, David Malkin, Daniel A Morgenstern
Publikováno v:
Paediatrics & Child Health.
Cancer is the leading cause of disease-related death in children, adolescents, and young adults beyond the newborn period in North America. Improving survival rates for patients with hard-to-cure cancer remains a challenge. One approach that has gain
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b53543e22190476cc5de70b8ecd1c49d
https://doi.org/10.1093/pch/pxac123
https://doi.org/10.1093/pch/pxac123
Autor:
Margarida Simao Rafael, Amer Shammas, Sarah Cohen-Gogo, Daniel A. Morgenstern, Meredith S. Irwin, Reza Vali
Publikováno v:
PET Clinics. 16:419-427
Theranostics combines diagnosis and targeted therapy, achieved by the use of the same or similar molecules labeled with different radiopharmaceuticals or identical with different dosages. One of the best examples is the use of metaiodobenzylguanidine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe5ccf428b8a59f694b5284636cf060b
https://doi.org/10.1016/j.cpet.2021.03.006
https://doi.org/10.1016/j.cpet.2021.03.006
Autor:
Amer Shammas, Rebecca J. Deyell, Carol Portwine, Paul Moorehead, Mateo Farfan, Reza Vali, Margarida Simao Rafael, Daniel A. Morgenstern, Nida Usmani, Thuvaraha Vanniyasingam, Meredith S. Irwin
Publikováno v:
Pediatric Blood & Cancer. 68
Background Meta-iodobenzylguanidine(MIBG) scans are used to detect neuroblastoma metastatic lesions at diagnosis and during posttreatment surveillance. MIBG positivity following induction chemotherapy correlates with poor outcome; however, there are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7eb5896f337918fac596d5211bd391a4
https://doi.org/10.1002/pbc.29289
https://doi.org/10.1002/pbc.29289
Autor:
Benjamin Lerman, Yimei Li, Meaghan Granger, Thomas Cash, Arhanti Sadanand, Katherine Somers, Aeesha Ranavaya, Michelle Choe, Jennifer Foster, Daniel A. Morgenstern, Margarida Simao Rafael, Keri A. Streby, Rachel Zeno, Rajen Mody, Sahr Yazdani, Ami Vijay Desai, Margaret E Macy, Suzanne Shusterman, Sara Michele Federico, Rochelle Bagatell
Publikováno v:
Journal of Clinical Oncology. 40:10025-10025
10025 Background: Encouraging responses to chemoimmunotherapy with I/T/DIN/GM-CSF have been observed in trials for patients (pts) with relapsed/refractory HR-NBL, but factors associated with response have not been identified and duration of response
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::40f6b740a2a387769fe7f0a9f2b4405d
https://doi.org/10.1200/jco.2022.40.16_suppl.10025
https://doi.org/10.1200/jco.2022.40.16_suppl.10025